J Periodontal Res:晚期糖基化终末产物增加人口腔上皮细胞Lipocalin 2表达

2020-04-07 lishiting MedSci原创

糖尿病(DM)是牙周疾病的风险因素,能够加重牙周炎的致病状态。DM并发症的一个主要因素为晚期糖基化终末产物(AGEs),它会在牙周组织中累积并导致炎症反应。Lipocalin 2 (LCN2)是一种抗

糖尿病(DM)是牙周疾病的风险因素,能够加重牙周炎的致病状态。DM并发症的一个主要因素为晚期糖基化终末产物(AGEs),它会在牙周组织中累积并导致炎症反应。Lipocalin 2 (LCN2)是一种抗微生物肽和炎症相关因子,并且LCN2在DM中的表达水平明显增加。这篇研究的目的是为了评估AGEs和牙龈卟啉单胞菌脂多糖(P g-LPS)对人口腔上皮细胞(TR146 cells)中LCN2的影响以及LCN2分泌在牙周炎合并DM患者中所扮演的角色。

研究分别在AGEs (AGE2)和对照BSA培养条件下或添加了P g-LPS时,体外培养TR146细胞并检测细胞活性。从上皮细胞培养液中提取条件培养基并制备溶解产物,通过WB和ELISA检测LCN2, RAGE, IL-6, MAPK和NF-κB。提取AGE处理过的TR146细胞和分化的HL-60 (D-HL-60)细胞RNA,通过实时定量PCR检测LCN2和白细胞介素-6 (IL-6)的mRNAs。将RAGE-和LCN2-siRNAs (siRAGE, siLCN2)转染上皮细胞,检测AGE诱导的LCN2表达。D-HL-60细胞与TR146细胞共培养,转染siLCN2并施以AGEs刺激,检测D-HL-60细胞中IL-6 mRNA的表达以及细胞迁移情况。

结果显示,AGEs增加人上皮细胞中LCN2和IL-6的表达水平。siRAGE和RAGE中和抗体能够抑制AGE诱导的LCN2表达。AGEs促进上皮细胞中ERK, p38和NF-κB磷酸化,而它们的抑制剂会抑制AGE诱导的LCN2。相反,P g-LPS并未显著增加表达Toll-like receptor 2的TR146细胞中LCN2的表达水平。在共培养实验中,AGE诱导的LCN2抑制D-HL-60细胞中IL-6 mRNA表达,并且在上皮细胞中敲除LCN2会抑制HL-60细胞的迁移。

结论:结果表明,AGEs通过RAGE, MAPK和NF-κB信号通路增加口腔上皮细胞中 LCN2的表达,LCN2的分泌可能会影响牙周炎合并DM患者的致病状态。

原始出处:

Rie Kido, Yuka Hiroshima, et al. Advanced Glycation End-Products Increase Lipocalin 2 Expression in Human Oral Epithelial Cells. J Periodontal Res., 2020 Mar 13[Online ahead of print]

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1728393, encodeId=c81d1e28393b4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 00:08:39 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927939, encodeId=9e7f192e939f6, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 02 00:08:39 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318315, encodeId=e979131831536, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510844, encodeId=7aac1510844bd, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533910, encodeId=25ac1533910a7, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-06-10 feather89
  2. [GetPortalCommentsPageByObjectIdResponse(id=1728393, encodeId=c81d1e28393b4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 00:08:39 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927939, encodeId=9e7f192e939f6, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 02 00:08:39 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318315, encodeId=e979131831536, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510844, encodeId=7aac1510844bd, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533910, encodeId=25ac1533910a7, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2021-01-02 smlt2008
  3. [GetPortalCommentsPageByObjectIdResponse(id=1728393, encodeId=c81d1e28393b4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 00:08:39 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927939, encodeId=9e7f192e939f6, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 02 00:08:39 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318315, encodeId=e979131831536, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510844, encodeId=7aac1510844bd, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533910, encodeId=25ac1533910a7, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-04-09 lfyang
  4. [GetPortalCommentsPageByObjectIdResponse(id=1728393, encodeId=c81d1e28393b4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 00:08:39 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927939, encodeId=9e7f192e939f6, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 02 00:08:39 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318315, encodeId=e979131831536, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510844, encodeId=7aac1510844bd, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533910, encodeId=25ac1533910a7, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=)]
    2020-04-09 dzx0922892
  5. [GetPortalCommentsPageByObjectIdResponse(id=1728393, encodeId=c81d1e28393b4, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed Jun 10 00:08:39 CST 2020, time=2020-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927939, encodeId=9e7f192e939f6, content=<a href='/topic/show?id=f7fb13216dc' target=_blank style='color:#2F92EE;'>#OCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13216, encryptionId=f7fb13216dc, topicName=OCA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Sat Jan 02 00:08:39 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1318315, encodeId=e979131831536, content=<a href='/topic/show?id=b5dde6644b1' target=_blank style='color:#2F92EE;'>#糖基化#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=76644, encryptionId=b5dde6644b1, topicName=糖基化)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=43cb463, createdName=lfyang, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510844, encodeId=7aac1510844bd, content=<a href='/topic/show?id=f98210002a8' target=_blank style='color:#2F92EE;'>#IPO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10002, encryptionId=f98210002a8, topicName=IPO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0a1910256881, createdName=dzx0922892, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533910, encodeId=25ac1533910a7, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Apr 09 03:08:39 CST 2020, time=2020-04-09, status=1, ipAttribution=)]

相关资讯

Diabetes Care:高温烹饪食物或可增加胰岛素抵抗

研究要点: 1、高AGEs饮食增加胰岛素抵抗的发生;2、调整烹饪方法可减少AGEs含量,从而降低IR发生风险;3、摄入果糖对AGEs含量没有影响。 高温烹饪食物可导致晚期糖基化终产物(AGEs)的形成, AGEs被认为可引起2型糖尿病患者葡萄糖代谢受损。此外,大量摄取果糖可能会影响内源性AGEs的形成。【原文下载】 为了研究果糖的摄取或烹饪方式影响食物的AGE含量后,是否会影

SCI REP:晚期糖基化终末产物对健康超重成人炎症和心血管风险的影响!

这些研究结果表明摄入低晚期糖基化终产物饮食两周并不能改善超重和肥胖成人的炎症和心血管状况。

Diabetologia:低AGE饮食对糖尿病患者有益

晚期糖基化终末产物(AGEs)是一组随着衰老、糖尿病以及肾功能衰竭逐渐积累于循环组织中的性质各异的分子。根据最近的研究结果,肥胖和代谢综合征成年人摄入低AGE饮食与对照组相比,可显著改善胰岛素抵抗、氧化应激、炎症和体重等方面。 来自西奈山医学院的Helen Vlassara博士和同事们对138名50岁以上肥胖和代谢综合征(符合代谢综合征5天诊断中的2条或以上)参与者进行了一项随机对照试验。参

PNAS:痴呆症或是“吃”出来的

最近,发表在《国家科学院院刊》上的一项研究指出,晚期糖基化终末产物(AGEs)的化合物可能是淀粉样蛋白积累的一个原因。饮食能够促进血液中AGEs水平升高。近日刊登在美国《国家科学院院刊》上的一项研究指出,一种被称为晚期糖基化终末产物(AGEs)的化合物可能是淀粉样蛋白积累的一个原因,这种蛋白与阿尔兹海默氏症有关。出现在西方饮食中的AGEs此前也被与糖尿病和神经退行性疾病联系在一起。与年龄有关的痴呆

J Periodon Res:晚期糖基化终末产物增加人口腔上皮细胞脂钙蛋白2的表达

糖尿病(DM)是牙周病的危险因素,会加重牙周病的严重程度。 糖尿病并发症的主要因素之一是晚期糖基化终末产物(AGEs)在牙周组织中积累并引起炎症反应。